| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 50 | 2023 | 4840 | 1.590 |
Why?
|
| Skin Diseases | 16 | 2021 | 368 | 1.390 |
Why?
|
| Erythrasma | 1 | 2024 | 1 | 0.950 |
Why?
|
| Arm | 1 | 2024 | 138 | 0.910 |
Why?
|
| Skin | 23 | 2016 | 1290 | 0.790 |
Why?
|
| Insect Bites and Stings | 1 | 2021 | 42 | 0.770 |
Why?
|
| Silicones | 2 | 2015 | 60 | 0.680 |
Why?
|
| Buttocks | 2 | 2015 | 14 | 0.610 |
Why?
|
| Ethics, Professional | 1 | 2016 | 25 | 0.540 |
Why?
|
| Smartphone | 1 | 2016 | 45 | 0.520 |
Why?
|
| Unnecessary Procedures | 1 | 2016 | 101 | 0.510 |
Why?
|
| Foreign-Body Reaction | 1 | 2015 | 31 | 0.500 |
Why?
|
| Cosmetic Techniques | 1 | 2015 | 23 | 0.490 |
Why?
|
| Dermatomycoses | 2 | 2006 | 42 | 0.490 |
Why?
|
| Microscopy | 1 | 2016 | 193 | 0.480 |
Why?
|
| Pathology, Clinical | 1 | 2016 | 155 | 0.480 |
Why?
|
| Interprofessional Relations | 1 | 2016 | 211 | 0.470 |
Why?
|
| Diagnosis, Differential | 22 | 2024 | 4897 | 0.450 |
Why?
|
| Dysplastic Nevus Syndrome | 4 | 2016 | 56 | 0.440 |
Why?
|
| Nevus, Pigmented | 4 | 2002 | 116 | 0.430 |
Why?
|
| Dermatologic Surgical Procedures | 4 | 2003 | 107 | 0.420 |
Why?
|
| Choriocarcinoma | 1 | 2012 | 49 | 0.410 |
Why?
|
| Subcutaneous Fat | 1 | 2012 | 67 | 0.400 |
Why?
|
| Lipoma | 1 | 2012 | 94 | 0.390 |
Why?
|
| Mohs Surgery | 4 | 2010 | 102 | 0.360 |
Why?
|
| Referral and Consultation | 1 | 2016 | 935 | 0.360 |
Why?
|
| Polychondritis, Relapsing | 2 | 2006 | 7 | 0.350 |
Why?
|
| Leg | 3 | 2024 | 218 | 0.350 |
Why?
|
| Keratosis, Actinic | 2 | 2023 | 39 | 0.350 |
Why?
|
| Drug Eruptions | 4 | 2016 | 271 | 0.340 |
Why?
|
| Hyperkeratosis, Epidermolytic | 2 | 2002 | 6 | 0.330 |
Why?
|
| Precancerous Conditions | 4 | 2016 | 1066 | 0.330 |
Why?
|
| Humans | 130 | 2024 | 270947 | 0.310 |
Why?
|
| Carcinoma, Basal Cell | 3 | 2002 | 288 | 0.310 |
Why?
|
| Colonic Diseases | 1 | 2009 | 74 | 0.310 |
Why?
|
| Testicular Neoplasms | 1 | 2012 | 554 | 0.300 |
Why?
|
| Skin Diseases, Vesiculobullous | 5 | 2016 | 25 | 0.290 |
Why?
|
| Melanoma | 9 | 2021 | 5523 | 0.280 |
Why?
|
| Nevus | 7 | 2002 | 116 | 0.280 |
Why?
|
| Penicillium | 1 | 2006 | 3 | 0.270 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2017 | 285 | 0.260 |
Why?
|
| Glucocorticoids | 3 | 2017 | 628 | 0.260 |
Why?
|
| Isotretinoin | 5 | 2003 | 161 | 0.250 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2006 | 191 | 0.250 |
Why?
|
| Pertussis Toxin | 1 | 2024 | 64 | 0.240 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2024 | 42 | 0.240 |
Why?
|
| Alopecia Areata | 2 | 2024 | 53 | 0.240 |
Why?
|
| Dermatologic Agents | 2 | 2003 | 47 | 0.240 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2024 | 98 | 0.240 |
Why?
|
| Administration, Intranasal | 1 | 2024 | 181 | 0.240 |
Why?
|
| Sarcoma, Kaposi | 3 | 2016 | 192 | 0.230 |
Why?
|
| Epidermal Cyst | 2 | 1994 | 47 | 0.230 |
Why?
|
| Paronychia | 1 | 2003 | 4 | 0.220 |
Why?
|
| Prednisone | 1 | 2006 | 1039 | 0.220 |
Why?
|
| Osteoma | 1 | 2002 | 9 | 0.220 |
Why?
|
| Panniculitis | 2 | 2015 | 58 | 0.210 |
Why?
|
| Bupivacaine | 1 | 2003 | 74 | 0.210 |
Why?
|
| Thigh | 3 | 2015 | 165 | 0.210 |
Why?
|
| Herpes Simplex | 1 | 2003 | 102 | 0.210 |
Why?
|
| Male | 62 | 2024 | 128454 | 0.200 |
Why?
|
| Ossification, Heterotopic | 1 | 2002 | 70 | 0.200 |
Why?
|
| Biopsy, Needle | 3 | 2017 | 1403 | 0.200 |
Why?
|
| Biopsy | 13 | 2017 | 3545 | 0.200 |
Why?
|
| Adjuvants, Immunologic | 2 | 2024 | 696 | 0.200 |
Why?
|
| Competency-Based Education | 1 | 2022 | 82 | 0.200 |
Why?
|
| Hypertrichosis | 1 | 2021 | 7 | 0.190 |
Why?
|
| Anesthetics, Local | 1 | 2003 | 175 | 0.190 |
Why?
|
| Hyperhidrosis | 1 | 2021 | 10 | 0.190 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 1994 | 559 | 0.190 |
Why?
|
| Larva | 1 | 2021 | 292 | 0.190 |
Why?
|
| Urticaria | 1 | 2001 | 28 | 0.180 |
Why?
|
| Ear, External | 1 | 2000 | 43 | 0.180 |
Why?
|
| Adult | 49 | 2015 | 81555 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 6 | 1993 | 370 | 0.170 |
Why?
|
| Acne Vulgaris | 5 | 2003 | 49 | 0.170 |
Why?
|
| Female | 56 | 2024 | 148509 | 0.160 |
Why?
|
| Papillomaviridae | 4 | 2002 | 642 | 0.160 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 1 | 1999 | 47 | 0.160 |
Why?
|
| Prostheses and Implants | 1 | 2000 | 295 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2023 | 5568 | 0.160 |
Why?
|
| Sebaceous Gland Neoplasms | 2 | 1993 | 99 | 0.150 |
Why?
|
| Keratosis | 4 | 1992 | 38 | 0.150 |
Why?
|
| Keratinocytes | 2 | 2015 | 247 | 0.150 |
Why?
|
| Eyebrows | 1 | 2017 | 18 | 0.150 |
Why?
|
| Tattooing | 1 | 2017 | 16 | 0.140 |
Why?
|
| Mouth Neoplasms | 2 | 1997 | 732 | 0.140 |
Why?
|
| Antineoplastic Agents | 8 | 2016 | 14679 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 3397 | 0.140 |
Why?
|
| Tumor Virus Infections | 3 | 2002 | 249 | 0.140 |
Why?
|
| Granuloma | 2 | 2015 | 159 | 0.140 |
Why?
|
| Tretinoin | 4 | 1987 | 621 | 0.140 |
Why?
|
| Granuloma, Pyogenic | 1 | 2016 | 10 | 0.140 |
Why?
|
| Middle Aged | 44 | 2017 | 90021 | 0.140 |
Why?
|
| Neurodermatitis | 1 | 2015 | 1 | 0.130 |
Why?
|
| Education, Medical, Graduate | 1 | 2022 | 696 | 0.130 |
Why?
|
| Imidazoles | 3 | 2015 | 1059 | 0.130 |
Why?
|
| Sarcoidosis | 1 | 2017 | 114 | 0.130 |
Why?
|
| Psoriasis | 3 | 1992 | 138 | 0.130 |
Why?
|
| Giant Cells | 1 | 2015 | 73 | 0.130 |
Why?
|
| Paget Disease, Extramammary | 1 | 2016 | 54 | 0.130 |
Why?
|
| Injections, Intradermal | 1 | 2015 | 51 | 0.130 |
Why?
|
| Enchondromatosis | 1 | 1995 | 4 | 0.130 |
Why?
|
| Folliculitis | 1 | 1994 | 7 | 0.120 |
Why?
|
| Oximes | 1 | 2015 | 193 | 0.120 |
Why?
|
| Dermatology | 2 | 1994 | 77 | 0.110 |
Why?
|
| Thromboangiitis Obliterans | 1 | 1993 | 3 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 2 | 2016 | 4510 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 7216 | 0.110 |
Why?
|
| Bowen's Disease | 1 | 1993 | 10 | 0.110 |
Why?
|
| Adenoma, Sweat Gland | 2 | 1984 | 13 | 0.110 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 1993 | 26 | 0.110 |
Why?
|
| Hemangioma | 2 | 1995 | 164 | 0.110 |
Why?
|
| Lipomatosis | 1 | 1992 | 23 | 0.110 |
Why?
|
| Erythema Nodosum | 1 | 1992 | 15 | 0.100 |
Why?
|
| Paraneoplastic Syndromes | 1 | 1993 | 85 | 0.100 |
Why?
|
| Elephantiasis | 1 | 1992 | 4 | 0.100 |
Why?
|
| Cryptorchidism | 1 | 2012 | 49 | 0.100 |
Why?
|
| Facial Neoplasms | 1 | 2012 | 79 | 0.100 |
Why?
|
| Scabies | 1 | 1991 | 3 | 0.100 |
Why?
|
| Arthritis, Gouty | 1 | 1991 | 9 | 0.100 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2012 | 83 | 0.100 |
Why?
|
| Pentazocine | 1 | 1991 | 4 | 0.100 |
Why?
|
| Scrotum | 1 | 2012 | 60 | 0.100 |
Why?
|
| Sweet Syndrome | 1 | 1992 | 35 | 0.100 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 1 | 2012 | 65 | 0.100 |
Why?
|
| Skin Diseases, Infectious | 2 | 1989 | 26 | 0.100 |
Why?
|
| Arthritis | 1 | 1993 | 149 | 0.100 |
Why?
|
| Herpes Zoster | 1 | 1992 | 53 | 0.100 |
Why?
|
| Orchiectomy | 1 | 2012 | 229 | 0.100 |
Why?
|
| Eyelid Neoplasms | 1 | 1993 | 197 | 0.100 |
Why?
|
| Condylomata Acuminata | 2 | 1996 | 32 | 0.100 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 7461 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2022 | 1432 | 0.090 |
Why?
|
| Lung Neoplasms | 2 | 2012 | 11761 | 0.090 |
Why?
|
| Hypospadias | 1 | 2012 | 80 | 0.090 |
Why?
|
| Botulinum Toxins | 1 | 1992 | 136 | 0.090 |
Why?
|
| Adenocarcinoma | 3 | 2016 | 7936 | 0.090 |
Why?
|
| Plant Lectins | 1 | 1990 | 28 | 0.090 |
Why?
|
| Rickettsia rickettsii | 1 | 2010 | 4 | 0.090 |
Why?
|
| Rocky Mountain Spotted Fever | 1 | 2010 | 8 | 0.090 |
Why?
|
| Immunotherapy | 2 | 2021 | 3532 | 0.090 |
Why?
|
| Pelvic Neoplasms | 1 | 1992 | 203 | 0.090 |
Why?
|
| Immunohistochemistry | 5 | 2017 | 7813 | 0.090 |
Why?
|
| Genital Neoplasms, Male | 1 | 1990 | 45 | 0.090 |
Why?
|
| Certification | 1 | 1991 | 109 | 0.090 |
Why?
|
| Dermatofibrosarcoma | 3 | 1995 | 73 | 0.090 |
Why?
|
| Aged | 22 | 2016 | 73161 | 0.090 |
Why?
|
| Elastic Tissue | 1 | 1989 | 36 | 0.080 |
Why?
|
| Fibroma | 2 | 1992 | 88 | 0.080 |
Why?
|
| Collagen | 2 | 1989 | 738 | 0.080 |
Why?
|
| Sensitivity and Specificity | 4 | 2016 | 5186 | 0.080 |
Why?
|
| Skin Diseases, Parasitic | 1 | 2009 | 8 | 0.080 |
Why?
|
| Antigens, CD | 4 | 1995 | 1436 | 0.080 |
Why?
|
| Potassium Iodide | 1 | 1988 | 1 | 0.080 |
Why?
|
| Schistosomiasis | 1 | 2009 | 65 | 0.080 |
Why?
|
| Hypergammaglobulinemia | 1 | 1988 | 23 | 0.080 |
Why?
|
| Calcinosis | 1 | 1991 | 432 | 0.080 |
Why?
|
| Antibodies, Bacterial | 1 | 2010 | 420 | 0.080 |
Why?
|
| Photography | 1 | 1988 | 127 | 0.080 |
Why?
|
| Adolescent | 15 | 2015 | 32577 | 0.070 |
Why?
|
| Immunoglobulin E | 1 | 1988 | 182 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 1318 | 0.070 |
Why?
|
| Morbidity | 1 | 2009 | 403 | 0.070 |
Why?
|
| Sweat Gland Neoplasms | 2 | 1993 | 71 | 0.070 |
Why?
|
| Epidermolysis Bullosa Acquisita | 1 | 2006 | 1 | 0.070 |
Why?
|
| Mycoses | 1 | 2010 | 396 | 0.070 |
Why?
|
| Foot | 2 | 2001 | 108 | 0.070 |
Why?
|
| Bacterial Infections | 1 | 2010 | 507 | 0.070 |
Why?
|
| Antimetabolites | 1 | 2006 | 77 | 0.070 |
Why?
|
| Thailand | 1 | 2006 | 35 | 0.070 |
Why?
|
| Hypothyroidism | 1 | 1988 | 211 | 0.070 |
Why?
|
| Collagen Diseases | 1 | 1985 | 5 | 0.070 |
Why?
|
| Immune Tolerance | 1 | 1988 | 425 | 0.070 |
Why?
|
| Aurothioglucose | 1 | 1985 | 1 | 0.070 |
Why?
|
| Gold Sodium Thiomalate | 1 | 1985 | 1 | 0.070 |
Why?
|
| Antifungal Agents | 3 | 2003 | 877 | 0.070 |
Why?
|
| Pemphigus | 1 | 1985 | 10 | 0.070 |
Why?
|
| Hematopoiesis | 1 | 1989 | 606 | 0.070 |
Why?
|
| Emigration and Immigration | 1 | 2006 | 96 | 0.060 |
Why?
|
| Bordetella pertussis | 1 | 2024 | 18 | 0.060 |
Why?
|
| Colon | 1 | 2009 | 689 | 0.060 |
Why?
|
| Microtomy | 2 | 1995 | 16 | 0.060 |
Why?
|
| Edema | 3 | 1991 | 263 | 0.060 |
Why?
|
| Lip Neoplasms | 1 | 1984 | 19 | 0.060 |
Why?
|
| Histiocytoma, Benign Fibrous | 2 | 1995 | 74 | 0.060 |
Why?
|
| Melanocytes | 3 | 1994 | 240 | 0.060 |
Why?
|
| Ipilimumab | 2 | 2021 | 758 | 0.060 |
Why?
|
| Transglutaminases | 2 | 1994 | 100 | 0.060 |
Why?
|
| Whooping Cough | 1 | 2024 | 60 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 3972 | 0.060 |
Why?
|
| Alternaria | 1 | 2003 | 5 | 0.060 |
Why?
|
| Graft vs Host Disease | 2 | 1992 | 2804 | 0.060 |
Why?
|
| Gold | 1 | 1985 | 266 | 0.060 |
Why?
|
| Global Health | 1 | 2009 | 693 | 0.060 |
Why?
|
| Isomerism | 1 | 2003 | 66 | 0.060 |
Why?
|
| Acyclovir | 1 | 2003 | 80 | 0.050 |
Why?
|
| Neoplasms | 4 | 2021 | 15849 | 0.050 |
Why?
|
| Administration, Topical | 1 | 2003 | 264 | 0.050 |
Why?
|
| Mucins | 3 | 1994 | 289 | 0.050 |
Why?
|
| T-Lymphocytopenia, Idiopathic CD4-Positive | 1 | 2002 | 4 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 547 | 0.050 |
Why?
|
| Darier Disease | 1 | 1982 | 8 | 0.050 |
Why?
|
| Genital Neoplasms, Female | 1 | 1990 | 790 | 0.050 |
Why?
|
| Staphylococcal Infections | 1 | 1988 | 684 | 0.050 |
Why?
|
| Animals | 3 | 2024 | 62771 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 1987 | 872 | 0.050 |
Why?
|
| Mycosis Fungoides | 2 | 1997 | 335 | 0.050 |
Why?
|
| Aged, 80 and over | 6 | 2016 | 30941 | 0.050 |
Why?
|
| Accreditation | 1 | 2022 | 136 | 0.050 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2005 | 303 | 0.050 |
Why?
|
| Professionalism | 1 | 2022 | 54 | 0.050 |
Why?
|
| Epidermis | 2 | 1994 | 201 | 0.050 |
Why?
|
| Connective Tissue Diseases | 2 | 1992 | 48 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2012 | 15253 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2012 | 4191 | 0.050 |
Why?
|
| Hepatitis C, Chronic | 1 | 2006 | 469 | 0.050 |
Why?
|
| Allylamine | 2 | 1990 | 11 | 0.050 |
Why?
|
| Clinical Competence | 2 | 2022 | 1324 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2003 | 459 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2003 | 1620 | 0.040 |
Why?
|
| Mass Screening | 1 | 2009 | 1554 | 0.040 |
Why?
|
| Amines | 2 | 1990 | 86 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2006 | 1445 | 0.040 |
Why?
|
| Carcinoma, Small Cell | 1 | 2002 | 427 | 0.040 |
Why?
|
| Hair | 2 | 1993 | 39 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2012 | 6837 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2005 | 958 | 0.040 |
Why?
|
| Ultraviolet Rays | 2 | 2016 | 588 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2024 | 1329 | 0.040 |
Why?
|
| Child | 6 | 2003 | 30418 | 0.040 |
Why?
|
| Consensus | 1 | 2023 | 1106 | 0.040 |
Why?
|
| Palatal Neoplasms | 1 | 1997 | 27 | 0.040 |
Why?
|
| False Negative Reactions | 2 | 1996 | 293 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2000 | 662 | 0.040 |
Why?
|
| Adenoma | 1 | 1983 | 741 | 0.040 |
Why?
|
| Triamcinolone | 1 | 2017 | 24 | 0.040 |
Why?
|
| Prognosis | 4 | 2006 | 22458 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 7240 | 0.040 |
Why?
|
| Granuloma Annulare | 1 | 1997 | 8 | 0.040 |
Why?
|
| Mice, Hairless | 1 | 2016 | 57 | 0.030 |
Why?
|
| Pancytopenia | 1 | 2017 | 119 | 0.030 |
Why?
|
| Heart | 1 | 2003 | 1211 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 3 | 2002 | 3494 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 2 | 1994 | 1372 | 0.030 |
Why?
|
| Lichen Planus | 1 | 1996 | 22 | 0.030 |
Why?
|
| Interferons | 1 | 1997 | 300 | 0.030 |
Why?
|
| Chronic Disease | 2 | 1991 | 1851 | 0.030 |
Why?
|
| Necrosis | 2 | 2015 | 603 | 0.030 |
Why?
|
| Papillomavirus Infections | 2 | 2002 | 1009 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2003 | 1255 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 1985 | 0.030 |
Why?
|
| CD3 Complex | 1 | 1997 | 322 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 1996 | 373 | 0.030 |
Why?
|
| Disease Progression | 2 | 2017 | 6893 | 0.030 |
Why?
|
| Retrospective Studies | 6 | 1995 | 39694 | 0.030 |
Why?
|
| Histocytological Preparation Techniques | 1 | 1995 | 18 | 0.030 |
Why?
|
| Nevus, Intradermal | 1 | 1994 | 2 | 0.030 |
Why?
|
| Tissue Embedding | 1 | 1995 | 29 | 0.030 |
Why?
|
| Suppuration | 1 | 1994 | 5 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2017 | 265 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2017 | 839 | 0.030 |
Why?
|
| Ploidies | 1 | 1995 | 257 | 0.030 |
Why?
|
| Foot Diseases | 1 | 1994 | 50 | 0.030 |
Why?
|
| Leprosy, Lepromatous | 1 | 1994 | 13 | 0.030 |
Why?
|
| Pathology, Surgical | 1 | 1995 | 87 | 0.030 |
Why?
|
| Interferon-alpha | 2 | 2002 | 960 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2012 | 33827 | 0.030 |
Why?
|
| Child, Preschool | 3 | 2003 | 16978 | 0.030 |
Why?
|
| DNA, Viral | 1 | 1996 | 763 | 0.030 |
Why?
|
| Skin Diseases, Bacterial | 1 | 1994 | 42 | 0.030 |
Why?
|
| Cicatrix | 1 | 1995 | 187 | 0.030 |
Why?
|
| Foot Ulcer | 1 | 1993 | 20 | 0.030 |
Why?
|
| Osteopoikilosis | 1 | 1992 | 7 | 0.030 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 1992 | 4 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 4505 | 0.030 |
Why?
|
| Extremities | 1 | 1994 | 307 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 675 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2016 | 360 | 0.030 |
Why?
|
| Chondrosarcoma | 1 | 1995 | 214 | 0.030 |
Why?
|
| Ocular Motility Disorders | 1 | 1992 | 43 | 0.030 |
Why?
|
| Elastin | 1 | 1992 | 50 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 1992 | 249 | 0.030 |
Why?
|
| Epithelium | 1 | 1994 | 805 | 0.030 |
Why?
|
| Antigens, CD34 | 4 | 1995 | 642 | 0.030 |
Why?
|
| Syndrome | 3 | 1992 | 1404 | 0.020 |
Why?
|
| Aluminum Hydroxide | 1 | 1991 | 40 | 0.020 |
Why?
|
| Dapsone | 2 | 1994 | 15 | 0.020 |
Why?
|
| Infant | 3 | 2001 | 13913 | 0.020 |
Why?
|
| Panniculitis, Lupus Erythematosus | 1 | 1991 | 3 | 0.020 |
Why?
|
| Incidence | 1 | 2021 | 5843 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 2017 | 1773 | 0.020 |
Why?
|
| Acantholysis | 1 | 1990 | 8 | 0.020 |
Why?
|
| Contraindications | 1 | 1991 | 154 | 0.020 |
Why?
|
| Exophthalmos | 1 | 1991 | 45 | 0.020 |
Why?
|
| Asphyxia | 1 | 1990 | 20 | 0.020 |
Why?
|
| Hemosiderin | 1 | 1990 | 6 | 0.020 |
Why?
|
| Salivary Glands, Minor | 1 | 1990 | 36 | 0.020 |
Why?
|
| Hand | 1 | 1991 | 175 | 0.020 |
Why?
|
| Clotrimazole | 1 | 1990 | 5 | 0.020 |
Why?
|
| Tinea Pedis | 1 | 1990 | 4 | 0.020 |
Why?
|
| Tinea | 1 | 1990 | 8 | 0.020 |
Why?
|
| Purpura | 1 | 1990 | 35 | 0.020 |
Why?
|
| Conjunctival Diseases | 1 | 1990 | 36 | 0.020 |
Why?
|
| Lymphangioma | 1 | 1990 | 35 | 0.020 |
Why?
|
| Vulvar Diseases | 1 | 1990 | 17 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 2351 | 0.020 |
Why?
|
| Spinal Dysraphism | 1 | 1994 | 264 | 0.020 |
Why?
|
| Methods | 1 | 1990 | 221 | 0.020 |
Why?
|
| Vascular Diseases | 1 | 1993 | 243 | 0.020 |
Why?
|
| Factor VIII | 1 | 1990 | 64 | 0.020 |
Why?
|
| Lectins | 1 | 1990 | 157 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 1990 | 206 | 0.020 |
Why?
|
| Endemic Diseases | 1 | 2010 | 69 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2016 | 1030 | 0.020 |
Why?
|
| Keratoacanthoma | 1 | 1989 | 19 | 0.020 |
Why?
|
| Orbital Diseases | 1 | 1991 | 121 | 0.020 |
Why?
|
| Mice | 2 | 2024 | 35992 | 0.020 |
Why?
|
| Leg Dermatoses | 1 | 1989 | 7 | 0.020 |
Why?
|
| Muscular Diseases | 1 | 1990 | 163 | 0.020 |
Why?
|
| Coxsackievirus Infections | 1 | 1989 | 11 | 0.020 |
Why?
|
| Frozen Sections | 1 | 1990 | 118 | 0.020 |
Why?
|
| Lymphocytes | 1 | 1994 | 1269 | 0.020 |
Why?
|
| Erythroblastosis, Fetal | 1 | 1989 | 33 | 0.020 |
Why?
|
| Parasitic Diseases | 1 | 2010 | 66 | 0.020 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2016 | 1088 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 1995 | 1961 | 0.020 |
Why?
|
| Hyalin | 1 | 1989 | 18 | 0.020 |
Why?
|
| Mycobacterium Infections | 1 | 1989 | 51 | 0.020 |
Why?
|
| Fresh Water | 1 | 2009 | 21 | 0.020 |
Why?
|
| Swimming | 1 | 2009 | 29 | 0.020 |
Why?
|
| Sclerosis | 1 | 1989 | 84 | 0.020 |
Why?
|
| Face | 1 | 1990 | 251 | 0.020 |
Why?
|
| Recurrence | 2 | 1988 | 4881 | 0.020 |
Why?
|
| United States | 1 | 2006 | 15983 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 1995 | 1740 | 0.020 |
Why?
|
| AIDS-Related Complex | 4 | 1989 | 13 | 0.020 |
Why?
|
| Eosinophilia | 1 | 1990 | 191 | 0.020 |
Why?
|
| Arthritis, Reactive | 1 | 1987 | 13 | 0.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2015 | 1331 | 0.020 |
Why?
|
| Vitiligo | 1 | 1987 | 16 | 0.020 |
Why?
|
| Hamartoma | 1 | 1989 | 119 | 0.020 |
Why?
|
| Autoimmune Diseases | 2 | 1990 | 425 | 0.020 |
Why?
|
| Keratoderma, Palmoplantar | 1 | 1987 | 9 | 0.020 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1995 | 920 | 0.020 |
Why?
|
| Glucans | 1 | 1987 | 20 | 0.020 |
Why?
|
| Sunlight | 1 | 1987 | 78 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 1992 | 16186 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 2 | 2012 | 4067 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 1989 | 316 | 0.020 |
Why?
|
| Amyloidosis | 1 | 1989 | 185 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 2335 | 0.020 |
Why?
|
| Eye Neoplasms | 1 | 1989 | 259 | 0.020 |
Why?
|
| Fetofetal Transfusion | 1 | 1989 | 186 | 0.020 |
Why?
|
| Virus Diseases | 1 | 2010 | 392 | 0.020 |
Why?
|
| Platelet Count | 1 | 1987 | 490 | 0.020 |
Why?
|
| Acute Disease | 1 | 1991 | 2515 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2010 | 465 | 0.020 |
Why?
|
| Pityriasis | 1 | 1985 | 2 | 0.020 |
Why?
|
| Stomatitis, Aphthous | 1 | 1985 | 6 | 0.020 |
Why?
|
| Palliative Care | 1 | 1997 | 2154 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2399 | 0.020 |
Why?
|
| Hemorrhage | 1 | 1990 | 742 | 0.020 |
Why?
|
| Cartilage | 1 | 1986 | 112 | 0.020 |
Why?
|
| Genomics | 1 | 2016 | 2817 | 0.020 |
Why?
|
| Sulfones | 1 | 1986 | 149 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 1990 | 556 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 1989 | 486 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 5161 | 0.010 |
Why?
|
| Neck Dissection | 1 | 1985 | 294 | 0.010 |
Why?
|
| DNA Probes, HPV | 2 | 1996 | 12 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 1989 | 726 | 0.010 |
Why?
|
| Sebum | 1 | 1983 | 2 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1994 | 6172 | 0.010 |
Why?
|
| Blotting, Southern | 2 | 1994 | 457 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1986 | 459 | 0.010 |
Why?
|
| Epidermodysplasia Verruciformis | 1 | 2002 | 22 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1986 | 567 | 0.010 |
Why?
|
| Cryosurgery | 1 | 1984 | 186 | 0.010 |
Why?
|
| Eczema | 1 | 1982 | 36 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 1997 | 13976 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 1995 | 2669 | 0.010 |
Why?
|
| Nose | 1 | 1983 | 137 | 0.010 |
Why?
|
| Leukemia, Myeloid | 1 | 1987 | 994 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 2 | 1994 | 1215 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 1994 | 8591 | 0.010 |
Why?
|
| Prospective Studies | 1 | 1995 | 13352 | 0.010 |
Why?
|
| Microscopy, Electron | 2 | 1992 | 735 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1984 | 1985 | 0.010 |
Why?
|
| Staining and Labeling | 2 | 1994 | 465 | 0.010 |
Why?
|
| Pregnancy | 2 | 1990 | 8043 | 0.010 |
Why?
|
| Texas | 1 | 2010 | 6415 | 0.010 |
Why?
|
| Time Factors | 1 | 2012 | 13112 | 0.010 |
Why?
|
| Random Allocation | 2 | 1990 | 747 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1994 | 9078 | 0.010 |
Why?
|
| Double-Blind Method | 3 | 1990 | 2618 | 0.010 |
Why?
|
| Combined Modality Therapy | 2 | 1994 | 9043 | 0.010 |
Why?
|
| Homosexuality | 2 | 1989 | 30 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 16593 | 0.010 |
Why?
|
| Skin Diseases, Viral | 1 | 1996 | 12 | 0.010 |
Why?
|
| Warts | 1 | 1996 | 23 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1997 | 463 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 1997 | 265 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 1996 | 226 | 0.010 |
Why?
|
| KB Cells | 1 | 1994 | 21 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 1985 | 5324 | 0.010 |
Why?
|
| Back | 1 | 1994 | 49 | 0.010 |
Why?
|
| Infusions, Intravenous | 2 | 1987 | 1438 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1996 | 1062 | 0.010 |
Why?
|
| Photopheresis | 1 | 1994 | 79 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1994 | 736 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 1994 | 6483 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2012 | 10698 | 0.010 |
Why?
|
| Histiocytes | 1 | 1993 | 95 | 0.010 |
Why?
|
| Rifampin | 1 | 1994 | 220 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 1992 | 166 | 0.010 |
Why?
|
| Esthetics | 1 | 1992 | 116 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1992 | 243 | 0.010 |
Why?
|
| Muscles | 1 | 1993 | 462 | 0.010 |
Why?
|
| Facial Dermatoses | 1 | 1991 | 23 | 0.010 |
Why?
|
| Sialadenitis | 1 | 1990 | 8 | 0.010 |
Why?
|
| Basal Cell Nevus Syndrome | 1 | 1990 | 20 | 0.010 |
Why?
|
| Antibodies, Antinuclear | 1 | 1990 | 52 | 0.010 |
Why?
|
| Ointments | 1 | 1990 | 24 | 0.010 |
Why?
|
| Eyelid Diseases | 1 | 1991 | 74 | 0.010 |
Why?
|
| Pregnancy in Diabetics | 1 | 1990 | 28 | 0.010 |
Why?
|
| Tryptophan | 1 | 1990 | 144 | 0.010 |
Why?
|
| Groin | 1 | 1990 | 78 | 0.010 |
Why?
|
| Keratoconjunctivitis Sicca | 1 | 1990 | 45 | 0.010 |
Why?
|
| Thoracic Injuries | 1 | 1990 | 99 | 0.010 |
Why?
|
| Albinism | 1 | 1989 | 17 | 0.010 |
Why?
|
| Cefoxitin | 1 | 1989 | 6 | 0.010 |
Why?
|
| Abdominal Injuries | 1 | 1990 | 121 | 0.010 |
Why?
|
| Fibrosis | 1 | 1993 | 744 | 0.010 |
Why?
|
| Amikacin | 1 | 1989 | 37 | 0.010 |
Why?
|
| Sjogren's Syndrome | 1 | 1990 | 104 | 0.010 |
Why?
|
| Immunocompetence | 1 | 1989 | 73 | 0.010 |
Why?
|
| Carcinoma in Situ | 1 | 1992 | 495 | 0.010 |
Why?
|
| Wounds, Penetrating | 1 | 1989 | 157 | 0.000 |
Why?
|
| Pedigree | 1 | 1992 | 1983 | 0.000 |
Why?
|
| Alleles | 1 | 1994 | 2508 | 0.000 |
Why?
|
| Base Sequence | 1 | 1994 | 5496 | 0.000 |
Why?
|
| Drug Evaluation | 1 | 1987 | 435 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1992 | 3075 | 0.000 |
Why?
|
| Transforming Growth Factor beta | 1 | 1992 | 1132 | 0.000 |
Why?
|
| HIV Seropositivity | 1 | 1987 | 155 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1989 | 1153 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1994 | 6789 | 0.000 |
Why?
|
| Remission Induction | 1 | 1992 | 3645 | 0.000 |
Why?
|
| Opportunistic Infections | 1 | 1987 | 238 | 0.000 |
Why?
|
| Fibroblasts | 1 | 1992 | 1669 | 0.000 |
Why?
|
| Drug Administration Schedule | 1 | 1990 | 3542 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1992 | 5782 | 0.000 |
Why?
|
| Secretory Rate | 1 | 1983 | 16 | 0.000 |
Why?
|
| Drug Therapy, Combination | 1 | 1989 | 2368 | 0.000 |
Why?
|
| Epilepsy | 1 | 1990 | 982 | 0.000 |
Why?
|
| Pain | 1 | 1990 | 1696 | 0.000 |
Why?
|
| Predictive Value of Tests | 1 | 1990 | 4983 | 0.000 |
Why?
|
| Burns | 1 | 1982 | 126 | 0.000 |
Why?
|
| Phenotype | 1 | 1992 | 6465 | 0.000 |
Why?
|
| Kidney | 1 | 1989 | 2261 | 0.000 |
Why?
|
| Lipids | 1 | 1984 | 659 | 0.000 |
Why?
|
| Immunity, Innate | 1 | 1982 | 688 | 0.000 |
Why?
|
| Inflammation | 1 | 1987 | 2527 | 0.000 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1984 | 5108 | 0.000 |
Why?
|
| Radiation Injuries | 1 | 1982 | 1472 | 0.000 |
Why?
|
| Liver | 1 | 1984 | 3126 | 0.000 |
Why?
|
| Clinical Trials as Topic | 1 | 1984 | 3862 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1982 | 5685 | 0.000 |
Why?
|